Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China
· Delayed Price · Currency is CNY 30.07
+2.10 (7.51%)
Apr 29, 2026, 2:35 PM CST
SHA:688319 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 700.13 | 586.1 | 494.29 | 546.68 | 485.29 | Upgrade
|
| Other Revenue | 4.03 | 2.75 | 1.83 | 0.8 | 1.86 | Upgrade
|
| Revenue | 704.16 | 588.86 | 496.12 | 547.48 | 487.15 | Upgrade
|
| Revenue Growth (YoY) | 19.58% | 18.69% | -9.38% | 12.38% | 52.18% | Upgrade
|
| Cost of Revenue | 63.17 | 29.77 | 36.73 | 43.01 | 28.36 | Upgrade
|
| Gross Profit | 641 | 559.09 | 459.39 | 504.48 | 458.79 | Upgrade
|
| Selling, General & Admin | 456.1 | 389.32 | 336.12 | 352.06 | 296.33 | Upgrade
|
| Research & Development | 132.9 | 134.23 | 114.73 | 121.99 | 56.36 | Upgrade
|
| Other Operating Expenses | 6.05 | 3.72 | 3.32 | 3.55 | 3.21 | Upgrade
|
| Operating Expenses | 608.26 | 537.47 | 455.89 | 489.78 | 364.9 | Upgrade
|
| Operating Income | 32.73 | 21.62 | 3.51 | 14.7 | 93.89 | Upgrade
|
| Interest Expense | -14.99 | -14.46 | -7.18 | -5.07 | -1.23 | Upgrade
|
| Interest & Investment Income | 1.1 | 5.36 | 3.6 | 7.55 | 5.19 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.09 | -0.25 | 0.07 | -0.21 | -0.19 | Upgrade
|
| EBT Excluding Unusual Items | 18.92 | 12.28 | -0.01 | 16.97 | 97.67 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | -0.03 | -0.15 | -0.15 | -0.05 | Upgrade
|
| Other Unusual Items | 12.96 | 10.06 | 15.77 | 26.83 | 9.57 | Upgrade
|
| Pretax Income | 31.89 | 22.3 | 15.62 | 43.65 | 107.19 | Upgrade
|
| Income Tax Expense | 9.99 | 6.58 | 4.18 | 17.07 | -0.77 | Upgrade
|
| Earnings From Continuing Operations | 21.9 | 15.72 | 11.44 | 26.58 | 107.96 | Upgrade
|
| Minority Interest in Earnings | 0.36 | 5.04 | 6.11 | - | - | Upgrade
|
| Net Income | 22.26 | 20.76 | 17.56 | 26.58 | 107.96 | Upgrade
|
| Net Income to Common | 22.26 | 20.76 | 17.56 | 26.58 | 107.96 | Upgrade
|
| Net Income Growth | 7.24% | 18.24% | -33.95% | -75.38% | 198.82% | Upgrade
|
| Shares Outstanding (Basic) | 405 | 405 | 405 | 405 | 385 | Upgrade
|
| Shares Outstanding (Diluted) | 405 | 405 | 405 | 405 | 385 | Upgrade
|
| Shares Change (YoY) | 0.01% | -0.01% | 0.07% | 5.22% | 5.61% | Upgrade
|
| EPS (Basic) | 0.05 | 0.05 | 0.04 | 0.07 | 0.28 | Upgrade
|
| EPS (Diluted) | 0.05 | 0.05 | 0.04 | 0.07 | 0.28 | Upgrade
|
| EPS Growth | 7.23% | 18.25% | -33.99% | -76.61% | 182.95% | Upgrade
|
| Free Cash Flow | 6.68 | -217.05 | -125.88 | -225.24 | -29.75 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | -0.54 | -0.31 | -0.56 | -0.08 | Upgrade
|
| Dividend Per Share | - | - | 0.038 | - | - | Upgrade
|
| Gross Margin | 91.03% | 94.94% | 92.60% | 92.14% | 94.18% | Upgrade
|
| Operating Margin | 4.65% | 3.67% | 0.71% | 2.69% | 19.27% | Upgrade
|
| Profit Margin | 3.16% | 3.52% | 3.54% | 4.85% | 22.16% | Upgrade
|
| Free Cash Flow Margin | 0.95% | -36.86% | -25.37% | -41.14% | -6.11% | Upgrade
|
| EBITDA | 66.2 | 50.4 | 30.62 | 40 | 116.93 | Upgrade
|
| EBITDA Margin | 9.40% | 8.56% | 6.17% | 7.31% | 24.00% | Upgrade
|
| D&A For EBITDA | 33.47 | 28.78 | 27.11 | 25.3 | 23.04 | Upgrade
|
| EBIT | 32.73 | 21.62 | 3.51 | 14.7 | 93.89 | Upgrade
|
| EBIT Margin | 4.65% | 3.67% | 0.71% | 2.69% | 19.27% | Upgrade
|
| Effective Tax Rate | 31.34% | 29.52% | 26.74% | 39.11% | - | Upgrade
|
| Revenue as Reported | 704.16 | 588.86 | 496.12 | 547.48 | 487.15 | Upgrade
|
| Advertising Expenses | 331.88 | 264.73 | 224.9 | 248.75 | 212.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.